Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth?
HALO's impending acquisition of Elektrofi will add Hypercon tech to broaden its drug delivery platform and support long-term growth.
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Butler - Citizens JMP Securities, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Rob, and I will be your conference operator today.
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Identify Superstar Stocks Like Halozyme with Money Flows
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Analysts Just Upgraded these Five Stocks
Bank of America reiterated its buy rating on Palantir with a price target of $180.
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO Tram Bui - Head of Investor Relations & Corporate Communications Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Brendan Mychal Smith - TD Cowen, Research Division Corinne Johnson - Goldman Sachs Group, Inc., Research Division Jason Nicholas Butler - Citizens JMP Securities, LLC, Research Division Michael Gennaro DiFiore - Evercore ISI Institutional Equities, Research Division Mitchell Swaroop Kapoor - H.C.
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
